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Abstract
Background: Following entry, uncoating, and reverse transcription, a number of cellular proteins become
associated with the Human Immunodeficiency Virus type 1 (HIV-1) pre-integration complex (PIC). With the goal of
obtaining reagents for the analysis of the HIV-1 PIC composition and localisation, we have constructed functional
integrase (IN) and matrix (MA) proteins that can be biotinylated during virus production and captured using
streptavidin-coated beads.
Results: Although the labelled C-terminus allows for the sensitive detection of virion-associated IN, it becomes
inaccessible in the presence of cellular proteins. This masking is not dependent on the nature of the tag and does
not occur with the tagged MA. It was not observed either with an IN mutant unable to interact with LEDGF/p75,
or when LEDGF/p75 was depleted from cells.
Conclusion: Our observation suggests that a structural rearrangement or oligomerization of the IN protein occurs
during the early steps of infection and that this process is related to the presence of LEDGF/p75.
Background
Integration of the Human Immunodeficiency Virus
(HIV) DNA into the host cell chromosome mediated by
the integrase (IN) protein is an obligatory step of the
virus life cycle. This endonuclease encoded by the pol
gene generates active CA-3’-hydroxyl ends on the viral
cDNA and catalyses strand transfer with the chromoso-
mal DNA. IN is also involved in the processing and traf-
ficking of the viral genome throughout the pre-
integration phase including reverse transcription and
nuclear import [1-3]. The IN protein is organized in
three domains: an N-terminal domain (NTD) involved
in higher order multimerization (residues 1-49), a cataly-
tic core domain (CCD) (residues 50-212) and a C-term-
inal domain (CTD) (residues 213-288) with DNA
binding activity. IN activity is modulated by its interac-
tions with viral and cellular proteins within the Pre-Inte-
gration Complex (PIC) [1,2]; these interactions protect it
from degradation [4,5], target it to the relevant cell
compartment [6,7] and enhance its catalytic activity
[1,8,9]. Among the cellular partners of IN, the most stu-
died and characterized is LEDGF/p75 [1,8,10], a stress-
induced transcription co-activator that binds the IN
CCD [11,12] and tethers the viral cDNA to transcrip-
tionally active regions of the genome [13]. PICs have
not been fully characterized yet due to the limited quan-
tity of material that can be purified from HIV infected
cells. Yet, a complete identification of PIC components
could provide new targets for antiviral therapy and help
to target the integration of lentiviral vectors used in
gene therapy [14]. Our initial goal in this study was to
generate a tagged integrase that could be biotinylated
for streptavidin-mediated capture and purification of
PICs. Our data indicate that an active C-terminally
tagged IN can be generated and efficiently incorporated
into virions. However, we show that the C-terminal tag
is not accessible for capture in the context of the PIC.
This masking of the IN C-terminus is dependent on the
presence of LEDGF. It is consistent with a structural
remodelling of IN that is believed to occur during PIC
formation in HIV infected cells.
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Production and characterization of an HIV-based lentiviral
vector containing a tagged integrase
We tagged HIV-1 IN at its C-terminus by adding a 22
amino-acid Biotin Acceptor Domain (BAD) which can
be biotinylated in vivo in the presence of Bir A, a biotin
ligase from E. coli [15,16]. A VSV-G pseudotyped lenti-
viral vector encoding GFP was prepared using gag-pol
expression constructs with either the wild-type (IN-WT)
or the tagged IN (IN-BAD) sequence (Fig. 1A), and a
construct expressing the BirA gene was included in all
lentiviral vector preparations. The presence of the BAD
tag and its biotinylation by BirA did not affect the
amounts of p24
gag antigen released from transfected
cells (not shown) nor the vector titre measured in GFP
transducing units (Fig. 1B). The kinetics of viral DNA
synthesis (Fig. 1C) and integration (Fig. 1D) determined
by PCR [17] over 72 hours following transduction were
identical for IN-BAD and IN-WT vectors. We con-
cluded that the activity of the tagged IN was undistin-
guishable from that of the parental protein.
Biotinylation and capture of IN-BAD
IN-BAD and IN-WT vector preparations were analysed by
Western blot using anti-IN or anti-Biotin antibodies. Fig-
ure 2A shows that the tagged integrase displaying the
expected size difference was correctly incorporated into
virions and biotinylated (lane 1). Comparable amounts of
tagged and wild-type integrase were present in the respec-
tive virions, indicating that the BAD addition did not affect
viral proteins synthesis and assembly. We tested the possi-
bility to capture the tagged integrase by lysing virions and
incubating them with paramagnetic streptavidin-coated
beads. Bound material was eluted and analysed by Wes-
tern blot. The data in Figure 2A (lanes 3 and 4) indicate
an efficient and specific capture of IN-BAD on streptavi-
din beads. IN-BAD was not recovered from the unbound
fraction, contrary to IN-WT, indicating a very efficient
capture (Fig. 2A, lanes 5 and 6).
Capture of IN-BAD from lysates of infected cells
HEK 293 cells were transduced with the IN-BAD vector
(IN-BADv) or mock-transduced, and whole cell extracts
were prepared, as described in Materials and methods,
and incubated with streptavidin-coated beads. The
eluted material was analysed by Western blot. Figure 2B
demonstrates the selective SA capture of the biotiny-
lated IN from cell extracts (left panel). However, this
capture was inefficient, with an average of 30 minutes
exposure needed to visualize the protein in repeated
experiments. No associated LEDGF/p75 could be
revealed when the membrane was reprobed with an
anti-LEDGF/p75 antibody (not shown). Control
immunoprecipitations (IP) i n d i c a t e dt h a tb o t hM Aa n d
p24 proteins were readily detected in the same cell
extracts (Fig. 2B, middle panels). The experiment was
repeated using a lentiviral vector in which the integrase
was C-terminally tagged with an HA epitope (IN-HAv)
(see Materials and methods). Here again the integrase was
efficiently immunoprecipitated with an anti-HA antibody
from the lysed IN-HAv, but was poorly pulled down by
the same antibody from HEK 293 cells transduced with
the IN-HAv (Fig. 2B right panel). Finally, when a BAD tag
was inserted into the MA protein (see Materials and meth-
ods), the MA-BAD was incorporated into virions (MA-
BADv) and efficiently recovered from infected cells using
the same conditions of transduction, lysis, and SA capture
used in the IN-BAD experiment (Fig. 2C). As a control,
we checked that when IN-BAD virions were applied to
HEK 293 cells at 4°C for 4 hours before washing with K
buffer, no viral material was detected in the cell lysate in
pull down experiments (not shown). We concluded that
the biotinylated tag at the C-terminus of the IN protein,
which can be detected in virions, becomes inaccessible for
streptavidin binding after entry into the cell.
Efficient co-immunoprecipitation of integrase
and LEDGF/p75
The minute amount of pulled-down IN could have been
due to an early dissociation from PICs and degradation
or due to masking of the biotinylated tag in the context
of PICs. To resolve these issues, we analysed the pre-
sence of IN in our samples (the same extract used in SA
capture experiment shown in Fig. 2B) by co-immuno-
precipitation with LEDGF/p75, which is reportedly asso-
ciated with functional PICs [18]. Using this approach,
the IN-BAD was readily detected (1 minute exposure) in
HEK 293 IN-BADv (Fig. 3A). This indicated that IN had
not been degraded, but rather was kept in a configura-
tion where the biotinylated tag could not react with
streptavidin. PCR analysis on the pulled down material
from the anti LEDGF/p75 IP shown in Fig. 3A or from
the SA capture shown in Fig. 2B indicated that the viral
DNA was associated with the integrase, whether
LEDGF/p75 was present (co-immunoprecipitation) (Fig.
3B, bottom) or not (SA capture) (Fig. 3B, top). Negative
PCR controls included transductions made in the pre-
sence of azidothymidine (AZT) (Fig. 3B) as well as
immunoprecipitation with Protein A beads alone, or a
control IgG1 isotype, or a p24 monoclonal antibody
which does not precipitate PICs (not shown).
The presence of LEDGF/p75 in infected cells prevents
access to the IN C-terminus
We next asked whether the presence of LEDGF/p75 in
cells lysates could be linked directly or indirectly to the
Benkhelifa-Ziyyat et al. Retrovirology 2010, 7:27
http://www.retrovirology.com/content/7/1/27
Page 2 of 10Figure 1 Fusion of the Biotin Acceptor Domain (BAD) to the IN C-terminus does not affect particle production, cDNA synthesis, and
integration. (A) Amino acid sequence at the C-terminus of IN-BAD, in the context of a p8.74 derived gagpol expression construct. (B)
Comparison of vector titres obtained with IN-BAD and IN-WT. Data represent the mean ± SD of GFP titres measured on HCT116 cells from three
independent productions. (C) Kinetics of HIV-1 vector DNA synthesis during vector transduction of HEK 293 cells (30 ng of p24
gag/10
6 cells) with
or without AZT, analysed by quantitative PCR. (D) Amounts of integrated provirus. Data in C and D represent the mean ± SD of three
independent transductions.
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Page 3 of 10Figure 2 IN-BAD is efficiently biotinylated in producer cells and incorporated into virions. IN-BAD (lanes 1, 3) or IN-WT (lanes 2, 4) vector
particles (30 ng of p24
gag) were either untreated (lanes 1, 2) or incubated with streptavidin paramagnetic beads and eluted (SA capture, lanes 3,
4). Samples were run on SDS-PAGE and Western blots (WB) were analysed with anti-IN (top) or anti-biotin (bottom) antibodies (1 minute
exposure). Supernatants (spnt) from SA captures were also analysed (lane 5 and 6). (B) Left panel: streptavidin paramagnetic beads capture (SA
capture) of the biotinylated IN (IN-BAD) from extracts of 293 cells mock-transduced (Mock) or transduced with the IN-BAD vector (293 IN-BADv),
analysed by Western blotting with an anti-IN antibody. Middle panels: as controls, MA or p24 were immunoprecipitated (IP) respectively with an
anti-MA and an anti p24 antibodies from the same cells extracts and analysed by WB respectively with the same antibodies. Right panel: HA
tagged integrase (IN-HA) was immunoprecipitated with an anti-HA antibody from lysed IN-HA vector (IN-HAv) or from extracts of 293 cells
mock-transduced (Mock) or transduced with IN-HAv (293 IN-HAv) and analysed by Western blotting with an anti-IN antibody. (C) Streptavidin
paramagnetic beads capture of the biotinylated MA (MA-BAD) from extracts of 293 cells mock-transduced (Mock) or transduced with the MA-
BAD vector (293 MA-BADv), or from lysed MA-BAD vector (MA-BADv) analysed by Western blotting with an anti-IN antibody.
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Page 4 of 10masking of the IN C-terminal tag. Transductions of
HEK 293 cells and streptavidin beads capture from cell
lysates were repeated with IN-BAD virions containing a
Q168A mutant of IN (INQ168A-BADv). This mutation
modifies the interface between LEDGF/p75 and the IN
binding domain and, depending on the assay, abrogates
or severely reduces the interaction with LEDGF/p75
[10,11,19]. The data shown in Figure 4A confirmed the
absence of detectable interaction between the
INQ168A-BAD and LEDGF/p75 in infected cells (293
INQ168A-BADv, Fig. 4A lane 5). Another clear effect of
the IN mutation was to render the IN C-terminus acces-
sible for SA capture (Fig 4A, lane 3).
These data were confirmed using LEDGF/p75
depleted cells lysates. HEK 293 cells were transduced
with a lentiviral vector encoding GFP and a LEDGF/p75
shRNA [20] (HEK 293
sh cells) or with a control vector
(HEK 293
ctl cells). GFP
+ populations were generated
and analysed for vector genome copy numbers by qPCR
and LEDGF/p75 protein expression by Western blot.
Cell populations with around 10 copies of the vector
genome that expressed more than tenfold reduced levels
of LEDGF/p75 were subsequently used (sh, Fig. 4B).
Reduced levels of LEDGF/p75 were associated with slow
growth and increased cell death, as previously described
in attached cells [21,22]. Lentiviral transduction of these
LEDGF/p75 depleted cells was highly toxic, precluding
attempts to capture IN-BAD from lysates of infected
cells. Instead, we mixed lysates obtained from IN-BAD
particles (IN-BADv) and HEK 293 cells (293
ctl or 293
sh)
and asked whether IN-BAD could be captured on strep-
tavidin beads. IN-BAD co-immunoprecipitations with
LEDGF/p75 were performed as controls. As expected,
IN-BAD could be co-immunoprecipitated with LEDGF/
p75 when the IN-BADv was mixed with an HEK 293
ctl
cells lysate, but not with the HEK 293
sh lysate (Fig. 4B).
The masking of the IN-BAD C-terminus was again
observed when lysed IN-BAD particles were mixed with
an HEK 293
ctl lysate. In contrast the capture was
improved at least 9 fold when an HEK 293
sh cell lysate
was used. Altogether these results confirm that the IN-
BAD C-terminus is masked in the presence of LEDGF/
p75 protein in cell lysates
Discussion
The possibility to tag HIV-1 integrase without affecting
infectivity would allow its use as bait to purify and ana-
lyse PICs composition by biochemical methods
[15,23,24]. Here, we have added a biotinylable tag at the
C-terminus of IN (IN-BAD) and showed that the pro-
tein remains fully active in the context of a lentiviral
vector. The kinetics of viral DNA synthesis and integra-
tion were identical for IN-BAD and IN-WT vectors in
HEK 293 cells. IN-BAD is efficiently biotinylated and
Figure 3 (A) IN-BAD and LEDGF/p75 co-immunoprecipitation
from extracts of 293 cells mock-transduced (Mock) or
transduced with the IN-BADv (293 IN-BADv), analysed by
Western blotting with anti-LEDGF/p75 and anti-IN antibodies
(1 minute exposure). (B) PCR detection of viral DNA in streptavidin
capture (top) and LEDGF/p75 immunoprecipitates (bottom). 293
cells were transduced with the IN-BAD vector (293 IN-BADv) or
mock transduced (Mock) in the absence or presence of AZT.
Streptavidine capture or LEDGF/p75 co-immunoprecipitation were
performed on cell lysates, and vector DNA was detected using PCR
with the MH531 and MH532 primers [17]. The absence of
amplification in the presence of AZT indicates that only neo-
synthesized DNA was detected.
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Page 5 of 10Figure 4 Masking of the IN C-terminus in infected cells. (A) Streptavidin paramagnetic beads capture (SA capture) (1,2,3) or LEDGF/p75 co-
immunoprecipitation (4,5) of the biotinylated IN from extracts of 293 cells mock-transduced (lane 1) or transduced with the IN-BAD vector (293
IN-BADv) (lane 2, 4) or INQ168A-BAD vector (293 INQ168A-BADv (lane 3, 5) analysed by Western blotting with the anti-IN (top) or anti LEDGF/
p75 (bottom) antibodies (3 minutes exposure). (B) LEDGF/p75 co-immunoprecipitation or streptavidin capture of the biotinylated integrase from
extracts of 293
ctl (ctl) or 293
sh (sh) mixed with the IN-BAD vector (IN-BADv). As a control, equal amount of 293ctl or 293sh lysates were tested for
beta-actin content by WB (bottom panel).
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Page 6 of 10captured from virions on streptavidin coated beads.
Unexpectedly it is not efficiently pulled down from
infected cells, whereas it remains readily co-immunopre-
cipitated with LEDGF/p75. The biotin tag-mediated cap-
ture is however improved when LEDGF/p75 interaction
is abrogated either by a Q168A-IN mutation or by
LEDGF/p75 depletion from cells.
The addition of a biotinylable tag to the C-terminus of
IN and to MA has recently been reported in the context
of an infectious HIV-1NLX clone (respectively NLXINB
and NLXMAB). While tag insertion in MA was well tol-
erated, the C-terminal tagging of IN resulted in 40%
reduction in the virus titer in MAGI-5 cells and in inte-
grase activity in vitro [15]. In SupT1 cells, replication
kinetics of NLXINB is delayed in comparison to either
NLX or NLXMAB. Furthermore the biotinylation of the
tagged integrase rendered this virus non-infectious in
MAGI-5 cells. The difference with our result may be
explained by the fact that experiments were conducted
with different viral and IN-tag nucleotide and protein
sequences. In the context of HIV-1NLX, the insertion of
the tag introduced a stop codon in the overlapping vif
gene. Although vif activity is irrelevant in the context of
SupT1 and MAGI cells, the modification may have cis-
acting consequences, for instance on mRNA splicing.
More importantly, the sequence of our pol-BAD junc-
tion is different from that of Belshan et al., who intro-
duced 4 additional amino acids (Leu Gly Gly Ser) at the
C-terminus of IN, upstream of the BAD [15]. Such a
minor difference may have an important impact, as it is
established that C-terminal modifications or tagging of
the HIV-1 IN may render the protein sensitive to addi-
tional modifications. For example the K(264/266/273)R
mutation of IN is without effect on viral replication
unless a C-terminal tag is added [25].
C-terminally-tagged IN has been used to probe inter-
actions with cellular proteins upon ectopic expression,
leading to the identification of LEDGF/p75 as the major
interactor [2,8,18,26]. We show here that LEDGF/p75
readily interacts with a naturally processed IN-BAD pre-
sent in virions and PICs. We confirm that this interac-
tion is DNA independent, and we observe that it limits
the accessibility of the IN C-terminus. The Integrase
Binding Domain (IBD) of LEDGF/p75 interacts with the
IN-CCD, but no interaction with the IN-CTD has been
documented [11,12,27]. It is therefore likely that the
masking we observe is indirect and due to a conforma-
tional change of IN induced by LEDGF/p75 binding.
The three IN domains are connected by flexible linkers
which probably allow a conformational variability and
different oligomerization states and catalytic properties
[28]. For instance, it was shown that IN can undergo a
metal dependent conformational change, which results
in the loss of recognition by CCD and CTD-specific
antibodies [29,30]. Moreover, a DNA-induced protein
conformational change leading to connection of these two
domains has recently been described [31,32]. The Michel
et al. study [31] describes an intramolecular contact of the
IN-NTD with the IN-CTD in a complex containing 4 IN
and 2 LEDGF/p75 molecules, which represent the catalyti-
cally active form of the integrase [33,34]. The IN-CTD is
also known to contribute to IN multimerisation [35] and
promotes binding to different cellular proteins (Gemin2,
importin7, APOBEC3G, EED, p300) [26,36-39]. Our data
show that integrase capture from cell lysates through a C-
terminal tag is significantly improved when LEDGF/p75 is
depleted or when IN-LEDGF/75 interaction is abrogated.
We suggest that this change in accessibility of the C-ter-
minus reflects a LEDGF/p75 associated structural reorga-
nization of the protein.
In our experiment, LEDGF/p75 was not detected in
association with the small amounts of integrase attached
to streptavidin beads suggesting that only a LEDGF/
p75-free integrase may display an accessible C-terminal
tag. C-terminal masking was not detected in studies
where IN was over-expressed in cell lines [8,10,18].
Given the high concentration of IN expressed in these
cells, the stoichiometry of the interacting partners must
be significantly different from physiological conditions
in infected cells. The virion and PICs associated IN that
we study here are naturally cleaved from the gag-pol
precursor and are present at low concentrations. The
virion-borne IN may also carry modifications which
are not present on the ectopically expressed one. We
propose that depending on the experimental system,
two types of IN-LEDGF/p75 complexes may form: one
in which the C-terminus is accessible requiring high
IN concentrations, and possibly IN oligomerization;
and another one, mainly represented in infected cells
at low and physiological IN concentrations where the
C-terminus is masked. Unmasking at high IN concen-
tration could be due to a structural rearrangement led
by the titration of a second cellular partner whose con-
centration is limiting and/or by the absence of other
viral components of the PIC like MA and reverse tran-
scriptase (RT). Indeed, the RT protein which was
shown to be a PIC component interacts with the IN
CTD [40-42].
Conclusions
The addition of a biotinylable tag to the HIV-1 integrase
has allowed us to observe a dynamic change in the pro-
tein that takes place during the early steps of viral infec-
tion. This change is dependent on an interaction with
LEDGF/p75. Understanding its significance awaits
further progress in the characterization of the cellular
partners of PICs as well as the resolution of the com-
plete PIC structure.
Benkhelifa-Ziyyat et al. Retrovirology 2010, 7:27
http://www.retrovirology.com/content/7/1/27
Page 7 of 10Methods
Plasmids
The birA biotin ligase gene (NCBI accession number
AF044308) was amplified from E. coli genomic DNA by
PCR and introduced into the pcDNA (Invitrogen)
expression plasmid. For gag-pol expression constructs, a
22 amino-acid biotin acceptor domain (BAD) (Fig. 1A)
[16] was introduced in the pCMVΔR8.74 [43] either at
the C-terminus of IN (pCMVΔR8.74-IN-BAD) or in the
N-terminal region of MA. For pCMVΔR8.74-IN-BAD, a
450 pb IN fragment (F1) was PCR amplified with the
following primers (S1: 5’ TTTGGCATTCCCTA-
CAATCC3’), and (AS1: 5’CCAGAATTTGACGCAGA-
GAAGAAGCATCCTCATCCTGTCTACTTGCC 3’,
including the 22 terminal nt of IN in italics and 25 nt of
the BAD sequence, underlined). Oligonucleotides corre-
sponding to the complete BAD sequence plus 10 nt at
the 3’ end of IN were annealed (S2: 5’GGATGAG-
GATGCTTCTTCTCTGC-GTCAAATTCTGGATTCT-
CAAAAAATGGAATGG-CGTTC
TAACGCTGGTGGTTCTTAACACATGGAATTC-
TGCAACAAC 3’; EcoRI site in italics) and used in a
PCR fusion with F1 fragment using oligonucleotides
containing respectively AflII and EcoRI sites (S3: 5’
AGGCTGAACATCTTAAGACAGC 3’,A S 3 :5 ’TTGCA-
GAATTCCCGTTAAGAACC3’). The final PCR product
was digested with AflII and EcoRI and was swapped for
the corresponding fragment in pCMVΔR8.74. For
pCMVΔR8.74-MA-BAD, a BstBI unique site was added
by PCR to the 3’ end of the MA at position 383 of the
GAG coding sequence in the pCMVΔR8.74. A BstBI-
BAD linker was made by annealing S4 (5’-PO4-
CGAAGCTTCTTCTCTGCGTCAAATTCTGGATT-
CTCAAAAAATGGAATGGCGTTCTAACGCTGGT-
GGTTCTTT-3’, BAD inderlined) and AS5 (5’-PO4-
GCTTAGAACCACCAGCGTTAGAAC-GCCATTC-
CATTTTTTGAGAATCCAGAATTTGA-CGCAGA-
GAAGAAGCAA) which was ligated with the BstBI
digested pCMVΔR8.74. The HA tag was introduced at
the 3’-end of the pol gene of pCMVΔR8.74 by PCR
using primers S1 and AS4 (5’GCAGAATTCCATGTGT-
TAAGCGTAATCTGGAACATCGTATGG-GTACA-
TATCCTCATCCTGTCTACT 3’, HA tag underlined).
The PCR product was digested with AflII and EcoRI
and was swapped for the corresponding fragment in the
pCMVΔR8.74. The Q168A mutation was introduced in
pCMVΔR8.74-IN-BAD by PCR-directed mutagenesis,
using the Quick change II site directed mutagenesis kit
(Stratagene) and an oligonucleotide which contained
G C Gi np l a c eo ft h eC A Gc o d o ni np o s i t i o n5 0 1o ft h e
IN ORF (5’ GGACAGGTAAGAGATGCGGCTGAA-
CATCTTAAGAC 3’). The HIV-1-derived self-inactivat-
ing pRRL-H1shRNA
LEDGF/p75-PGK-eGFP-WPRE and
pRRL-H1shRNA
ctl-PGK-eGFP-WPRE transfer plasmids
were constructed from a previously described system [44].
Sense siRNA sequences targeting LEDGF/p75 and control
sequence were respectively AAAGACAGCATGAG-
GAAGCGA [20], TGTTTTAAGGGCCCCCCGT [44].
Cell culture
HEK 293T, HEK 293 and HCT116 cells were cultured
in Dulbecco’s modified eagle media (DMEM) supple-
mented with 10% foetal calf serum, 1% L-glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin
(Gibco BRL) at 37°C, 5% CO2.
Vector production and titrations
Production
VSV-G pseudotyped lentiviral vector encoding GFP
were prepared by transient transfection into 293T cells
[45]. For tagged vectors, gag-pol expression constructs
with tagged (IN-BAD or IN-HA) IN sequence or tagged
(MA-BAD) MA sequence were used. Briefly, cells were
seeded into 15 cm dishes at 10
6 cells per dish and trans-
fected 72 h later. A total of 60 μg of plasmid DNA was
used for the transfection of one dish: 14.6 μg of the gag-
pol construct, 7.9 μg of the envelope plasmid pMD.G,
22.5 μg of the transfer vector plasmid (pRRL-sin-PPT-
hPGK-GFP-WPRE or pRRL-H1shRNA
LEDGF/p75-PGK-
eGFP-WPRE or pRRL-H1shRNA
ctl-PGK-eGFP-WPRE).
For biotinylation, 15 μgo ft h ep c D N A b i r Ac o n s t r u c t
was included in IN-WT, IN-BAD or MA-BAD lentivec-
tor preparations. Vectors supernatants were collected
every 24 h for 96 h and concentrated by ultracentrifuga-
tion (20.000 rpm, 2 h), aliquoted, and stored at -80°C
until used.
Titrations
Titers of vector particles were obtained by measuring
the number of transducing units (TU/ml) in FACS ana-
lysis after limiting dilution in HCT116 cells or the
amount of p24 antigen released from the producing
cells (not shown). TU/ml were calculated as the number
of cells infected × percentage of GFP
+ cells/100 × dilu-
tion of vector. The p24 antigen concentration was deter-
mined by p24 core profile ELISA to estimate the titer of
PP (physical particles) based on the assumption that 1fg
of p24 represent 12pp [46].
Vector transduction and cells extracts
All transductions were done with vectors that have
equivalent TU/PP ratio. For proteins-BAD capture or
immunoprecipitations, fifteen million HEK 293 cells
were transduced (MOI 50) with IN-BAD or INQ168A-
B A Do rM A - B A Do rI N - H Av e c t o r so rm o c k - t r a n s -
duced. When necessary, azidothymidine (AZT) was
added 24 h before transduction at the final concentra-
tion of 100 μM. To remove vector excess, cells were
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hours post-infection. Six hours later, cells were washed
three times with K buffer (150 mM KCL, 20 mM
HEPES [pH 7.6], 5 mM MgCl2, 0.5% [vol/vol] Triton X-
100, 1 mM dithiothreitol supplemented with proteases
and phosphatases inhibitors cocktail (Roche)) [6] with-
out Triton X100 and cells extracts were prepared in
1 ml of K buffer.
For shRNA experiments, 10
6 HEK 293 cells were
transduced at different MOI (10, 20, 30) in thenpresence
of polybrene (4 μg/ml; Sigma Aldrich). After 3 rounds of
transduction over a period of 48 h, cells were cultured
for 3 weeks and enriched by sorting GFP
+ populations
using flow cytometry. For the analysis of LEGDF/p75
protein expression, cells protein extracts were prepared
from 10
7 cells that were lysed for 30 mn in K buffer.
For Q-PCR, DNA samples were prepared with the
Wizard Genomic DNA Extraction Kit (Promega).
Biotinylation analysis
To analyse the IN biotinylation status, IN-BAD and IN-
WT vector preparations were either directly loaded onto
an SDS PAGE or lysed 30 mn in K buffer and incubated
2h o u r sw i t h2 0μl of paramagnetic streptavidin-coated
beads before material elution and loading (10
7 particles
per lane). IN-BAD and IN-WT were revealed on Wes-
tern blots probed with an anti-IN antibody (8G4, NIH
AIDS Research and Reference Reagent Program) or an
anti-biotin antibody (Tebu-bio).
For immunoprecipitations, 2.5 μg of LEDGF/p75 (Ser-
otec) or p24 or MA (Tebu-bio) or HA (Roche) antibo-
dies were incubated 2 hours with 20 μlo fP r o t e i nA -
coated beads in 100 μl of K buffer and washed three
times to remove antibodies excess. 500 μl of cell lysates
were incubated overnight with 20 μl of Protein A-coated
beads pre-bound to the antibodies or with 20 μlo f
streptavidin-coated Dynabeads (Invitrogen) for BAD
capture and the eluted material was analysed by Wes-
tern blotting using the appropriate antibody.
Q-PCR and PCR
Q-PCR
The kinetics of viral DNA synthesis and integration of
IN-BAD or IN-WT vectors were determined by Q-PCR
following transduction (30 ng of p24
gag antigen per 10
6
HEK 293 cells, MOI 10) as described previously [17].
The number of vector copies per cell of the pRRL-
H1shRNA
LEDGF/p75-PGK-eGFP-WPRE or the pRRL-
H1shRNA
ctl-PGK-eGFP-WPRE was determined by
Q-PCR, amplifying from the genomic DNA the Wood-
chuck post-trancriptional regulatory element (WPRE)
sequences of the lentiviral vector in comparison with
the human albumin gene as previously described [44].
PCR
1/10 of beads of the streptavidin pull downs or the
LEDGF/p75 co-immunoprecipitation were diluted in 10
μl of Tris/EDTA buffer and subjected to a PCR using
the MH531 and MH532 oligonucleotides [17] to amplify
total HIV-1 DNA. The HIV-1-derived self-inactivating
pRRLsin-hPGK-eGFP-WPRE transfer plasmid was used
as a positive control (not shown).
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